Saturday, July 11, 2026

pharma · Myasthenia Gravis, Generalized

Tang-Du Hospital

Tang-Du Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Myasthenia Gravis, Generalized. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
2
Patents
0
Clinical program

Tocilizumab Injectable Product

Phase 2 · small molecule · Myasthenia Gravis, Generalized

Tocilizumab Injectable Product for Myasthenia Gravis, Generalized is a Phase 2 program (small_molecule) at Tang-Du Hospital with 1 ClinicalTrials.gov record(s).

← All Tang-Du Hospital projects Phase 2 small molecule active

Internal code V4.0, 20220410

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Tang-Du Hospital
Phase
Phase 2
Modality
small_molecule
Indication
Myasthenia Gravis, Generalized
Status
active
Trials
1